Member Info for Chrisatrdg

Important development for all companies and research centres, including @Sareumplc, to aid targeting of therapy and patient selection
BIA@BIA_UK· Feb 6
A landmark study, involving 1,300 scientists, has mapped the mutations that drive cancer's development??
'Cancer was like a 100,000-piece jigsaw, and that until today, 99% of the pieces were missing'
Read more??
https://bbc.co.uk/news/health-51391151?intlink_from_url=https://www.bbc.co.uk/news/science_and_environment&link_location=live-reporting-story

https://twitter.com/sparksinsurrey/status/1225397417555775488

Further modification on link below '
'Last modified:
February 2020'
https://ec.europa.eu/inea/en/connecting-europe-facility/cef-energy/5.1.3-0036-uk-s-m-15
Is this the final modification cash soon?

Great news today on the day that I have finally sent my last share certificate to Interactive Investors for registration to enable me to convert them into ADD's next week.Well done Summit for achieving its milestone.

Good post Fredd1eboy & is why we should support the Directors in their efforts to keep the company afloat anything else is shere madness.

Extract from an e-mailI I received from the EU following my own enquiry received e-mail 29th January:
'The goal of this Action was to perform the Front End Engineering and Design (FEED) study for the Islandmagee Storage Facility and carry out the in situ downhole testing to determine the stress state of the Permian salt. The PCI 5.1.3 concerns the development of a salt cavity gas storage facility located in Larne (UK). More Information on the outcome of the Action will be published on the website of INEA shortly:
https://ec.europa.eu/inea/en/connecting-europe-facility/cef-energy/5.1.3-0036-uk-s-m-15 '

Physiomics PLC @Physiomics 1h
BBC News - Artificial intelligence-created medicine to be used on humans for first time
https://twitter.com/Physiomics

S/BE ADD'S

Great news I have heard today from Interactive Investors that I can convert my Ord shares on AIM into AAD's at no cost within a limited period.I have just converted my first lot of shares now waiting for share certificates from Barclays.

Hitesh Mistry
@hilseth_mistrov3h
New article: "Small models for big data" by myself and
@d_orrell
: https://ascpt.onlinelibrary.wiley.com/doi/abs/10.1002/cpt.1770…. Behind a paywall but an old blog-post, "Big data versus big theory", covers key points: http://systemsforecasting.com/2017/02/big-data-versus-big-theory/…: models derived from Big Data will be smaller than you think
Edit: I wonder where this may lead us.

Hi dawski37 I am now not going to the AGM but you have my full support for the actions you intend to take.It should be an interesting AGM & there will be no hiding for anyone from INFA however if this Company goes to where I think it can we will all
be very grateful to JW & his team.

Prostate cancer remains a high profile problem in the UK. @Physiomics continues to support the search for a cure through its work with @CellCentric and, separately through its grant-funded personalised dosing tool https://twitter.com/Physiomics/status/1222518563942150144

I Have now received a reply from the EU concerning the EU funding not sure where we are with the money.
'Dear Mr XXXXX,
Thank you very much for your email.
The current Action “Front End Engineering & Design Study and In situ Downhole Testing" (5.1.3-0036-UK-S-M-15) is part of PCI 5.1.3 Development of the Islandmagee Underground Gas Storage (UGS) facility at Larne (Northern Ireland). The Action 5.1.3-0036-UK-S-M-15 started in July 2016 ended in December 2018.
The goal of this Action was to perform the Front End Engineering and Design (FEED) study for the Islandmagee Storage Facility and carry out the in situ downhole testing to determine the stress state of the Permian salt. The PCI 5.1.3 concerns the development of a salt cavity gas storage facility located in Larne (UK). More Information on the outcome of the Action will be published on the website of INEA shortly:
https://ec.europa.eu/inea/en/connecting-europe-facility/cef-energy/5.1.3-0036-uk-s-m-15
For further information, you may also consult the following websites: https://www.infrastrataplc.com/ and https://www.islandmageeenergy.com
Thank you very much.

Best regards,
etc etc

Based on todays SP rise can we now safely say the SP bubble has finally burst & that with this weeks AGM we can all start moving back into profit.Its been a long wait but not long now hopefully.

Hi Hammo -
1) If you hold share certificates & do not wish to hold anymore then Sell before listing on AIM ceases in February or Sell on AIM & Buy on NASDAQ (risk of conversion loss Selling/Buying).
2)Hold shares & you wish to go on the NASDAQ but not Sell find a platform that trades on the NASDAQ & get advise urgently I am now with Interactive Investments (II).
For me I am in the process of converting my shares with Barclays platform into a share certificate & then through Crest putting into my account with II on AIM & then through Crest onto the NASDAQ.Instructed Barclays 13th December certificates now in system on their way to me taken so long.
Where I already had share certificates I sent them to II yesterday receipt today & will start process above today.

https://twitter.com/Sareumplc
"Treatment with [TYK2/JAK1 inhibitor] PF-06700841 rapidly improves disease activity in patients with chronic plaque psoriasis by inhibiting pro-inflammatory cytokines that require TYK2 and JAK1 for signal transduction" https://ncbi.nlm.nih.gov/pubmed/31972249 $SAR.L #TYK2

https://alphablueocean.com

https://www.morningstar.co.uk/uk/news/AN_1556806919958529600/valirx-partners-with-alpha-blue-ocean-and-buys-ip-assets-of-fit-bio.aspx

Further support for Sareum's SDC-1801
'Molecular and Cellular Responses to the TYK2/JAK1 Inhibitor, PF 06700841, Reveal Reduction of Skin Inflammation in Plaque Psoriasis: TYK2/JAK1 inhibitor in plaque psoriasis. http://dlvr.it/RNgmbj'

https://twitter.com/CKGeelmuyden/status/1221414801341022209

Hi manversushorse - What is your platform if its Interactive Investors (II) I believe you can transfer direct from Barclays to II & its not too late.

It is a sad moment for me that Dr David Roblin is leaving Summit who I felt had been a great asset for the Company however as far as Summits C-Diff drug is concerned he may now feel at its Phase 3 trial stage not be able to add more but possible he could have done for their Discuva platform. I wonder who will replace him.